Prevalence, Causes, Severity, Impact, and Management of Chronic Pain in Australian General Practice Patients

Henderson, Joan; Harrison, Christopher; Britt, Helena; Bayram, Clare; Miller, Graeme

doi:10.1111/pme.12195

Cited by 106 publications

(99 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is notable that the estimated 33 % prevalence rate for chronic pain in the US appears to be higher when compared with other countries; for instance, sample estimates for India were approximately 13 % [4], while another study reported chronic pain in 22 % of women versus 17 % of men in a Danish sample [5]. Further, an Australian study reported chronic pain in 19 % of their primary care sample [6], while a Canadian study reported similar estimates in 2011 [7].…”

Section: Introductionmentioning

confidence: 86%

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

et al. 2015

View full text Add to dashboard Cite

Opioid analgesics have become a cornerstone in the treatment of moderate to severe pain, resulting in a steady rise of opioid prescriptions. Subsequently, there has been a striking increase in the number of opioid-dependent individuals, opioid-related overdoses, and fatalities. Clinical use of opioids is further complicated by an increasingly deleterious profile of side effects beyond addiction, including tolerance and opioid-induced hyperalgesia (OIH), where OIH is defined as an increased sensitivity to already painful stimuli. This paradoxical state of increased nociception results from acute and long-term exposure to opioids, and appears to develop in a substantial subset of patients using opioids. Recently, there has been considerable interest in developing an efficacious treatment regimen for acute and chronic pain. However, there are currently no well-established treatments for OIH. Several substrates have emerged as potential modulators of OIH, including the N-methyl-D-aspartate and γ-aminobutyric acid receptors, and most notably, the innate neuroimmune system. This review summarizes the neurobiology of OIH in the context of clinical treatment; specifically, we review evidence for several pathways that show promise for the treatment of pain going forward, as prospective adjuvants to opioid analgesics. Overall, we suggest that this paradoxical state be considered an additional target of clinical treatment for chronic pain.

show abstract

Section: Introductionmentioning

confidence: 86%

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

et al. 2015

View full text Add to dashboard Cite

show abstract

“…However, a web of evidence now consistently and irrefutably identifies musculoskeletal health conditions and pain of musculoskeletal origin as imparting profound morbidity and socioeconomic burden. [1][2][3][4][5][6] This burden is particularly pronounced in developed nations as evidenced by the 2010 Global Burden of Disease study. 3,6 In Australia, the burden of disease attributed to musculoskeletal conditions now exceeds that of all other chronic health conditions in terms of years lived with disability (a morbidity-only index), and is second only to cancer when considering disability-adjusted life years (a composite index of morbidity and mortality).…”

Section: Introductionmentioning

confidence: 99%

Models of care for musculoskeletal health in Australia: now more than ever to drive evidence into health policy and practice

Briggs¹,

Towler²,

Speerin³

et al. 2014

Aust. Health Review

View full text Add to dashboard Cite

Abstract.Musculoskeletal health conditions such as arthritis, osteoporosis and pain syndromes impart a profound socioeconomic burden worldwide, particularly in developed nations such as Australia. Despite the identified burden, substantial evidence-practice and care disparity gaps remain in service delivery and access that limit the potential for improved consumer outcomes and system efficiencies. Addressing these gaps requires a whole-of-sector response, supported by evidence-informed health policy. Models of care (MoCs) serve as a policy vehicle to embed evidence into health policy and guide practice through changes in service delivery systems and clinician behaviour. In Australia, MoCs for musculoskeletal health have been developed by networks of multidisciplinary stakeholders and are incrementally being implemented across health services, facilitated by dedicated policy units and clinical champions. A web of evidence is now emerging to support this approach to driving evidence into health policy and practice. Understanding the vernacular of MoCs and the development and implementation of MoCs is important to embracing this approach to health policy.What is known about the topic? The impact of musculoskeletal health conditions is profound. As the awareness around the magnitude of the impact of these conditions increases, the importance of system-wide policy responses and platforms for health service improvements is now recognised. The term 'models of care' is not new. It has been used for many years, mainly at the hospital level, for planning and delivering clinical services. However, over the past 8 years an alternative approach using health networks has been adopted for the development and implementation of models of care to achieve broad engagement and a wider and more sustainable scope for implementation. What does this paper add? Here, we provide a rationale for the development of models of care for musculoskeletal health and draw on experience in their development and implementation using a health network model, referring to an emerging web of evidence to support this approach. We describe what models of care are, how they are developed and question whether they make a difference and what the future may hold. What are the implications for practitioners? All indications suggest that models of care are here to stay. Therefore, this paper provides practitioners with a contemporary overview of models of care in Australia, their relevance to musculoskeletal healthcare, particularly related to closing evidence-practice gaps, and opportunities for sector engagement.

show abstract

“…107 (Chronic pain was defined as pain experienced every day for 3 months in the 6 months prior to this consultation 108 ) A subsequent analysis of SAND substudies [109][110][111] showed the prevalence increased with patient age (Figure 14.5). Of 2,217 patients aged 65 years or older, 1 in 3 (32.8%) had chronic pain.…”

Section: Patients Aged 65+ Years With Chronic Painmentioning

confidence: 99%

Prioritising general practice research

Winzenberg

Gill

2016

Medical Journal of Australia

View full text Add to dashboard Cite

Prevalence, Causes, Severity, Impact, and Management of Chronic Pain in Australian General Practice Patients

Cited by 106 publications

References 73 publications

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

Targeting Opioid-Induced Hyperalgesia in Clinical Treatment: Neurobiological Considerations

Models of care for musculoskeletal health in Australia: now more than ever to drive evidence into health policy and practice

Prioritising general practice research

Contact Info

Product

Resources

About